New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
09:34 EDTJNJJanssen announces positive CHMP opinion for Vokanamettm in type 2 diabetes
Janssen-Cilag International NV of Johnson & Johnson announced that the Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion, recommending marketing authorization in the European Union for the medicinal product VOKANAMETTM, a fixed-dose therapy combining canagliflozin and immediate release metformin in a single tablet, intended for the treatment of type 2 diabetes mellitus. Canagliflozin is currently available as INVOKANATM following approval in the European Union in November 2013. The CHMPís positive opinion recommending the approval of the fixed dose combination of canagliflozin and metformin is now referred to the European Commission. Janssen anticipates receiving the regulatory decision from the European Commission in the coming months.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2015
10:52 EDTJNJFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 18, 2015
08:11 EDTJNJIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
08:11 EDTJNJAduro Biotech receives milestone payment from Janssen
Aduro Biotech (ADRO) announced that it has received a milestone payment from Janssen Biotech (JNJ) for Aduro's submission of an Investigational New Drug, or IND, Application to the FDA for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro's license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metastatic castration-resistant prostate cancer.
November 16, 2015
14:38 EDTJNJGenmab confirms FDA approval of Darzalex
Subscribe for More Information
13:09 EDTJNJFDA approves Darzalex to treat multiple myeloma
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use